PDMI Paradigm Medical Industries Inc (CE)

Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced today that the Company is expanding its domestic and international reach with the addition of ten new independent sales representatives in the United States. In addition, the company plans to add fifteen new international distributors by the middle of this year. Paradigm Medical also expects to add an additional ten to fifteen new domestic sales representatives, selectively placed throughout the domestic market, by the beginning of the third quarter of 2009. This aggressive expansion of the Company's sales force is to meet the demand that will be created through new product releases, current unique products and new partnerships with other ophthalmic organizations.

"I am delighted to have assembled this dynamic and enthusiastic sales team, a much needed component to our success," said Paradigm Medical President Stephen Davis. "With a focus on providing our customers with critical insight to upcoming new and innovative products, our team will play a vital role in establishing relationships with existing and new clients. I am looking forward to working closely with them." Stephen Davis continues, "The U.S. ophthalmic diagnostic device market is a $250 million market and we intend to utilize the sales force so that we may not only grow our share of the market but also to expand the size of the market through new proprietary products and technology."

About Paradigm Medical Industries, Inc.

Headquartered in Salt Lake City, UT, Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. The Company is poised to capture a niche market within the Glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.

For more information, please visit: www.paradigm-medical.com

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Contact: Paradigm Medical Industries, Inc. Stephen Davis President 801-977-8970 www.paradigm-medical.com